Table of Contents Author Guidelines Submit a Manuscript
Journal of Nutrition and Metabolism
Volume 2016, Article ID 4280876, 8 pages
http://dx.doi.org/10.1155/2016/4280876
Research Article

Vitamin D3 Suppresses Class II Invariant Chain Peptide Expression on Activated B-Lymphocytes: A Plausible Mechanism for Downregulation of Acute Inflammatory Conditions

1Morehouse School of Medicine, Atlanta, GA, USA
2Texas A&M School of Medicine, Temple, TX, USA
3Michigan State University College of Human Medicine, Flint, MI, USA

Received 24 December 2015; Revised 17 March 2016; Accepted 18 April 2016

Academic Editor: Azeddine Ibrahimi

Copyright © 2016 Omar K. Danner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. K. Newell, R. P. Tobin, J. H. Cabrera et al., “TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation,” Journal of Leukocyte Biology, vol. 88, no. 4, pp. 779–789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. W. C. Chen, B. Vayuvegula, and S. Gupta, “1,25-Dihydroxyvitamin D3-mediated inhibition of human B cell differentiation,” Clinical and Experimental Immunology, vol. 69, no. 3, pp. 639–646, 1987. View at Google Scholar · View at Scopus
  3. S. Chen, G. P. Sims, X. C. Xiao, Y. G. Yue, S. Chen, and P. E. Lipsky, “Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation,” Journal of Immunology, vol. 179, no. 3, pp. 1634–1647, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Van Etten and C. Mathieu, “Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts,” Journal of Steroid Biochemistry and Molecular Biology, vol. 97, no. 1-2, pp. 93–101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Farr, P. C. DeRoos, S. Eastman, and A. Y. Rudensky, “Differential expression of CLIP:MHC class II and conventional endogenous peptide:MHC class II complexes by thymic epithelial cells and peripheral antigen-presenting cells,” European Journal of Immunology, vol. 26, no. 12, pp. 3185–3193, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Gelin, I. Sloma, D. Charron, and N. Mooney, “Regulation of MHC II and CD1 antigen presentation: from ubiquity to security,” Journal of Leukocyte Biology, vol. 85, no. 2, pp. 215–224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Reich, F. Zou, M. Sieńczyk, J. Oleksyszyn, B. O. Boehm, and T. Burster, “Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells,” Cellular Immunology, vol. 269, no. 2, pp. 96–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. X. Xu, B. Press, N. M. Wagle, H. Cho, A. Wandinger-Ness, and S. K. Pierce, “B cell antigen receptor signaling links biochemical changes in the class II peptide-loading compartment to enhanced processing,” International Immunology, vol. 8, no. 12, pp. 1867–1876, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Salaun, P. Romero, and S. Lebecque, “Toll-like receptor's two-edged sword: when immunity meets apoptosis,” European Journal of Immunology, vol. 37, no. 12, pp. 3311–3318, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. C. Marshall and B. Vallet, “Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome,” Critical Care Medicine, vol. 29, no. 7, pp. S99–S106, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. J. K. Tan, A. Aphale, R. Malaviya, Y. Sun, and A. B. Gottlieb, “Mechanisms of action of etanercept in psoriasis,” Journal of Investigative Dermatology Symposium Proceedings, vol. 12, no. 1, pp. 38–45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Jones, S. A. Strugnell, and H. F. DeLuca, “Current understanding of the molecular actions of vitamin D,” Physiological Reviews, vol. 78, no. 4, pp. 1193–1231, 1998. View at Google Scholar · View at Scopus
  13. C. Mathieu and L. Adorini, “The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents,” Trends in Molecular Medicine, vol. 8, no. 4, pp. 174–179, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. A. S. Dusso, A. J. Brown, and E. Slatopolsky, “Vitamin D,” American Journal of Physiology—Renal Physiology, vol. 289, no. 1, pp. F8–F28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Heine, K. Anton, B. M. Henz, and M. Worm, “1α,25-dihydroxyvitamin D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro,” European Journal of Immunology, vol. 32, no. 12, pp. 3395–3404, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. J. D. Stoeckler, H. A. Stoeckler, N. Kouttab, and A. L. Maizel, “1 α,25-dihydroxyvitamin D3 modulates CD38 expression on human lymphocytes,” Journal of Immunology, vol. 157, no. 11, pp. 4908–4917, 1996. View at Google Scholar · View at Scopus
  17. A. F. McGettrick and L. A. J. O'Neill, “Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis,” British Journal of Haematology, vol. 139, no. 2, pp. 185–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. J. W. Morgan, N. Kouttab, D. Ford, and A. L. Maizel, “Vitamin D-mediated gene regulation in phenotypically defined human B cell subpopulations,” Endocrinology, vol. 141, no. 9, pp. 3225–3234, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. M. A. West, R. P. A. Wallin, S. P. Matthews et al., “Enhanced dendritic cell antigen capture via Toll-like receptor-induced actin remodeling,” Science, vol. 305, no. 5687, pp. 1153–1157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. Slavin, J. M. Soos, O. Stuve et al., “Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity,” The Journal of Clinical Investigation, vol. 108, no. 8, pp. 1133–1139, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. O. Takeuchi and S. Akira, “Pattern recognition receptors and inflammation,” Cell, vol. 140, no. 6, pp. 805–820, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. K. Newell, J. VanderWall, K. S. Beard, and J. H. Freed, “Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 22, pp. 10459–10463, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Heine, U. Niesner, H.-D. Chang et al., “1,25-dihydroxyvitamin D3 promotes IL-10 production in human B cells,” European Journal of Immunology, vol. 38, no. 8, pp. 2210–2218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. P. T. Liu, S. Stenger, H. Li et al., “Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response,” Science, vol. 311, no. 5768, pp. 1770–1773, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. L. R. Matthews, Y. Ahmed, K. L. Wilson, D. D. Griggs, and O. K. Danner, “Worsening severity of vitamin D deficiency is associated with increased length of stay, surgical intensive care unit cost, and mortality rate in surgical intensive care unit patients,” American Journal of Surgery, vol. 204, no. 1, pp. 37–43, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. M. F. Holick, “Medical progress: vitamin D deficiency,” The New England Journal of Medicine, vol. 357, no. 3, pp. 266–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Binkley, D. Krueger, C. S. Cowgill et al., “Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 7, pp. 3152–3157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Dawson-Hughes, R. P. Heaney, M. F. Holick, P. Lips, P. J. Meunier, and R. Vieth, “Estimates of optimal vitamin D status,” Osteoporosis International, vol. 16, no. 7, pp. 713–716, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. H. K. Kinyamu, J. C. Gallagher, K. A. Rafferty, and K. E. Balhorn, “Dietary calcium and vitamin D intake in elderly women: effect on serum parathyroid hormone and vitamin D metabolites,” American Journal of Clinical Nutrition, vol. 67, no. 2, pp. 342–348, 1998. View at Google Scholar · View at Scopus
  30. M. F. Holick, “Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease,” The American Journal of Clinical Nutrition, vol. 80, no. 6, supplement, pp. 1678S–1688S, 2004. View at Google Scholar · View at Scopus
  31. E. May, K. Asadullah, and U. Zügel, “Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs,” Current Drug Targets: Inflammation and Allergy, vol. 3, no. 4, pp. 377–393, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. A. A. Litonjua and S. T. Weiss, “Is vitamin D deficiency to blame for the asthma epidemic?” Journal of Allergy and Clinical Immunology, vol. 120, no. 5, pp. 1031–1035, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Oren, A. Banerji, and C. A. Camargo Jr., “Vitamin D and atopic disorders in an obese population screened for vitamin D deficiency,” Journal of Allergy and Clinical Immunology, vol. 121, no. 2, pp. 533–534, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Yu, B. Fedoric, P. H. Anderson, A. F. Lopez, and M. A. Grimbaldeston, “Vitamin D3 signalling to mast cells: a new regulatory axis,” International Journal of Biochemistry and Cell Biology, vol. 43, no. 1, pp. 41–46, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. R. J. Looney, J. H. Anolik, D. Campbell et al., “B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab,” Arthritis and Rheumatism, vol. 50, no. 8, pp. 2580–2589, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. H. Anolik, D. Campbell, R. Felgar, J. Rosenblatt, F. Young, and R. J. Looney, “B lymphocyte depletion in the treatment of systemic lupus (SLE): phase I/II trial of rituximab (Rituxan®) in SLE,” Arthritis & Rheumatology, vol. 46, article S289, 2002. View at Google Scholar
  37. M. W. Vaisberg, R. Kaneno, M. F. Franco, and N. F. Mendes, “Influence of cholecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in F1(NZB×W) mice,” Journal of Clinical Laboratory Analysis, vol. 14, no. 3, pp. 91–96, 2000. View at Publisher · View at Google Scholar
  38. H. Bour-Jordan and J. A. Bluestone, “B cell depletion: a novel therapy for autoimmune diabetes?” The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3642–3645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Agerberth, J. Charo, J. Werr et al., “The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations,” Blood, vol. 96, no. 9, pp. 3086–3093, 2000. View at Google Scholar · View at Scopus
  40. J.-P. Truman, M. L. Ericson, C. J. M. Choqueux-Seebold, D. J. Charron, and N. A. Mooney, “Lymphocyte programmed cell death is mediated via HLA class II DR,” International Immunology, vol. 6, no. 6, pp. 887–896, 1994. View at Publisher · View at Google Scholar · View at Scopus
  41. B. S. Nikolajczyk, “B cells as under-appreciated mediators of non-auto-immune inflammatory disease,” Cytokine, vol. 50, no. 3, pp. 234–242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. J. F. Aloia, M. Patel, R. DiMaano et al., “Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration,” American Journal of Clinical Nutrition, vol. 87, no. 6, pp. 1952–1958, 2008. View at Google Scholar · View at Scopus
  43. R. P. Heaney, “Vitamin D: criteria for safety and efficacy,” Nutrition Reviews, vol. 66, no. 10, supplement 2, pp. S178–S181, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Vieth, “Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety,” American Journal of Clinical Nutrition, vol. 69, no. 5, pp. 842–856, 1999. View at Google Scholar · View at Scopus